Forum Archive Index - May 2002

["G Stolwyk" <stolwyk@wave.co.nz>]

14-MAY-2002 TUE 09: 15 STEPHEN KWIK FAX NO. 98897607
D2E7 - RECEIPT OF FIRST MILESTONE PAYMENT FROM ABBOlT
On April 9 2002, Abbott Laboratories announced that it had submitted a Biologic License
Application to the US Food and Drug Administration and a Marketing Authorisation
Application to the European Agency for the Evaluation of Medicinal Products seeking
approval to market D2E7 for rheumatoid arthritis. Peptech has previously informed the ASX
that its TNF antibody patent is licensed to Knoll AG, which was acquired by Abbott in March,
2001. Under the license agreement, Peptech was due to receive a milestone payment upon
the above submission.
This announcement confirms the receipt of that milestone payment.
Peptech's ManaginQ Director, Stephen Kwik. commented "We can look forward to the receipt
of two more milestone payments one due upon approval from the MAA in Europe and the
second upon first commercial shipment. Abbott has recently forecasted peak sales of US51
billion with sales expected to commence in 2003".
Dr Paul Schober
Investor Relations
14 May 2002